使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good afternoon, and thank you for standing by. Welcome to the Supernus Pharmaceuticals Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. Instructions will follow at that time. Please be advised that today's conference is being recorded. I now will hand the conference over to Peter Vozzo of ICR, Healthcare Investor Relations Representative for Supernus Pharmaceuticals. Please go ahead.
下午好,感謝各位稍候。歡迎參加 Supernus Pharmaceuticals 2026 年第三季財務業績電話會議。目前所有與會者皆為僅收聽模式。在講者簡報結束後,將進行問答環節。屆時將提供相關指示。請注意,今日會議將被錄音。現在我將把會議交給 ICR 的 Peter Vozzo,他是 Supernus Pharmaceuticals 的醫療保健投資人關係代表。請開始。
Peter Vozzo - IR Contact Officer
Peter Vozzo - IR Contact Officer
Thank you, Angela. Good afternoon, everyone, and thank you for joining us today for Supernus Pharmaceuticals' Third Quarter 2026 Financial Results Conference Call. Today, after the close of the market, the company issued a press release announcing these results. On the call with me today are Supernus' Chief Executive Officer, Jack Khattar, and Chief Financial Officer, Tim Dec. Today's call is being made available via the investor relations section of the company's website at ir.supernus.com. Before we begin, I'd like to remind you that we will be making forward-looking statements. All these statements are based on the beliefs and expectations of management as of today. Actual events or results could differ materially.
謝謝你,Angela。各位下午好,感謝各位今天參加 Supernus Pharmaceuticals 2026 年第三季財務業績電話會議。今天在收盤後,公司發布新聞稿公布本次業績。今天與我一同參與電話會議的有 Supernus 執行長 Jack Khattar 與財務長 Tim Dec。今天的電話會議將透過公司網站投資人關係專區 ir.supernus.com 提供。開始之前,我想提醒各位,我們將發表前瞻性陳述。所有這些陳述均基於管理層截至今日的信念與預期。實際事件或結果可能與之存在重大差異。
We refer you to the documents we and Indivior Pharmaceuticals have filed with the SEC, including in periodic reports under the heading Risk Factors, which identify important factors that could cause actual results to differ materially from those expressed by the company verbally, as well as statements made within this afternoon's press release. This call is being webcast live, and a link can be found at the Supernus website at ir.supernus.com, and a replay will be made available shortly after this call is concluded. I'll now turn the call over to Jack.
我們請各位參閱我們以及 Indivior Pharmaceuticals 向美國證券交易委員會(SEC)提交的文件,包括定期報告中「風險因素」標題下的內容,其中列示了可能導致實際結果與公司口頭表述以及今日下午新聞稿所載陳述存在重大差異的重要因素。本次電話會議將進行即時網路直播,連結可於 Supernus 網站 ir.supernus.com 找到;在本次電話會議結束後不久也將提供重播。現在我把電話交給 Jack。
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Thank you, Peter. Good afternoon, everyone, and thanks for taking the time to join us on today's call. Today, we will focus on Supernus' strong 2026 third quarter and year-to-date results, which show the continued momentum across our commercial portfolio, specifically our growth products. After walking through these results, I'll provide a brief update on our transformative merger with Indivior Pharmaceuticals. For the third quarter of 2026, combined revenues of our growth products, Qelbree, ZURZUVAE, ONAPGO, and GOCOVRI, increased by 43% compared to the same period last year. Starting with Qelbree in the third quarter, prescriptions as reported by IQVIA grew by 18% over the third quarter of 2025, outpacing the 10% growth in the ADHD market. Net sales were $91 million in the third quarter, representing a 12% increase over last year.
謝謝你,Peter。各位下午好,感謝各位撥冗參加今天的電話會議。今天我們將聚焦 Supernus 2026 年第三季及年初至今的強勁業績,這些結果顯示我們商業產品組合(尤其是成長型產品)持續保持動能。在回顧這些結果之後,我將就我們與 Indivior Pharmaceuticals 的變革性合併提供簡要更新。2026 年第三季,我們成長型產品 Qelbree、ZURZUVAE、ONAPGO 與 GOCOVRI 的合計營收較去年同期成長 43%。先看 Qelbree,第三季處方量(依 IQVIA 報告)較 2025 年第三季成長 18%,優於 ADHD 市場 10% 的成長。第三季淨銷售額為 9,100 萬美元,較去年成長 12%。
Similarly, for the nine months ended September 30, 2026, Qelbree achieved robust growth of 18% in prescriptions and 15% in net sales compared to the same period last year. Net sales for the nine-month period reached an all-time high of $258 million. Qelbree's growth over the last year continues to come from both patient populations, with third quarter adult prescription growth of 25% and pediatric prescription growth of 16%. In addition, the total quarterly number of prescribers for Qelbree reached a high of approximately 46,000. Moving on to ONAPGO, during the third quarter of 2026, ONAPGO generated net sales of $17.1 million, up 27% compared to the second quarter of 2026. Demand for the product continued to be healthy, with more than 400 enrollment forms submitted in the quarter. In the third quarter of 2026, prescriptions grew by 17% compared to the second quarter of 2026.
同樣地,截至 2026 年 9 月 30 日止的前九個月,Qelbree 的處方量較去年同期強勁成長 18%,淨銷售額成長 15%。前九個月淨銷售額創下歷史新高,達 2.58 億美元。過去一年 Qelbree 的成長持續來自兩類病患族群,第三季成人處方成長 25%,兒科處方成長 16%。此外,Qelbree 的季度開立處方醫師總數達到約 46,000 名的高點。接著看 ONAPGO,2026 年第三季 ONAPGO 產生淨銷售額 1,710 萬美元,較 2026 年第二季成長 27%。產品需求持續健康,本季提交的加入/登記表格超過 400 份。2026 年第三季處方量較 2026 年第二季成長 17%。
As we announced last week, the FDA has recognized seven years of orphan drug exclusivity for ONAPGO for the treatment of motor fluctuations in adults with advanced Parkinson's disease. This designation validates the urgent need for targeted therapies and helps safeguard convenient innovation in a long-underserved community. In addition, we submitted a supplemental new drug application to the FDA for a second source of supply, with approval expected by mid-year 2027. Switching to ZURZUVAE, Supernus reported $42 million in collaboration revenues in the third quarter and $105 million for the nine-month period year to date. Full third quarter 2026 U.S. ZURZUVAE sales, as reported by Biogen, increased approximately by 53% compared to the same period in 2025. In the third quarter of 2026, ZURZUVAE saw strong growth in demand with written prescriptions growing 43% and the number of prescribers growing 42% compared to the same period last year.
如同我們上週所宣布,FDA 已認可 ONAPGO 針對治療晚期帕金森氏症成人之運動波動,享有 7 年的孤兒藥市場獨占期。此項認定驗證了對標靶治療的迫切需求,並有助於在長期服務不足的社群中保障便利的創新。此外,我們已向 FDA 提交補充新藥申請(sNDA),以新增第二供應來源,預期於 2027 年年中獲得核准。再看 ZURZUVAE,Supernus 於第三季認列合作收入 4,200 萬美元,年初至今前九個月為 1.05 億美元。依 Biogen 報告,2026 年第三季美國 ZURZUVAE 的完整季度銷售額較 2025 年同期約成長 53%。2026 年第三季,ZURZUVAE 需求強勁成長,書面處方量較去年同期成長 43%,開立處方醫師數較去年同期成長 42%。
Since launch, 87% of the prescriptions have come from repeat prescribers, and more than 43,000 patients have been treated with Zerzuva.
自上市以來,87% 的處方來自重複開立處方的醫師,且已有超過 43,000 名病患接受 Zerzuva 治療。
Since launch, 87% of the prescriptions have come from repeat prescribers, and more than 43,000 patients have been treated with ZURZUVAE. Switching now to GOCOVRI for the third quarter, the brand grew 4% in net sales and in prescriptions compared to the same period last year. Net sales reached an all-time high of $43 million in the third quarter. Moving on to R&D, the SPN-820 and SPN-817 phase IIb studies continue to enroll subjects with major depressive disorder and focal seizures, respectively. The SPN-443 program is expected to start a phase I single ascending and multiple ascending dose study in adult healthy volunteers by the end of 2026. Now turning to the status of our transformative merger with Indivior Pharmaceuticals. I'm pleased to report that Supernus and Indivior shareholders voted to approve the merger on October 15, and we expect this transaction to close on November 2nd.
自上市以來,87% 的處方來自重複開立處方的醫師,且已有超過 43,000 名病患接受 ZURZUVAE 治療。接著看第三季的 GOCOVRI,該品牌的淨銷售額與處方量較去年同期均成長 4%。第三季淨銷售額創下歷史新高,達 4,300 萬美元。再談研發方面,SPN-820 與 SPN-817 的 IIb 期研究分別持續招募重度憂鬱症與局灶性癲癇受試者。SPN-443 計畫預期於 2026 年底前,在成人健康受試者中啟動 I 期單次遞增劑量與多次遞增劑量研究。現在更新我們與 Indivior Pharmaceuticals 變革性合併的進展。我很高興報告,Supernus 與 Indivior 股東已於 10 月 15 日投票通過合併案,我們預期該交易將於 11 月 2 日完成交割。
As you may have seen earlier today, Indivior's results for the three months and nine months ended September 30th, 2026, were also strong and driven by continued record performance of SUBLOCADE. Combined with Supernus' solid performance and outlook, the new company will be starting from a position of strength with significant earnings and cash flow potential. The combined company will have a commercial portfolio of 11 differentiated medicines across psychiatry, neurology, and addiction, with key growth products currently expected to continue growing well into the 2030s. In addition, we will have the profitability, cash flow generation, and financial capacity to pursue further growth opportunities, including driving growth in our existing commercial portfolio, advancing our novel pipeline, and pursuing future business development. Our near-term priorities are to work through the integration of the two companies, ensure that our key growth drivers remain on track, and to progress our pipeline.
如各位今天稍早可能已看到,Indivior 截至 2026 年 9 月 30 日止三個月及九個月的業績同樣強勁,主要由 SUBLOCADE 持續創紀錄的表現所帶動。結合 Supernus 穩健的表現與展望,新公司將以強勢起點出發,具備可觀的獲利與現金流潛力。合併後公司將擁有 11 項具差異化的商業化藥品組合,涵蓋精神醫學、神經科學與成癮治療領域;目前預期關鍵成長型產品可持續成長至 2030 年代。此外,我們也將具備獲利能力、現金流創造能力與財務量能,以追求進一步的成長機會,包括推動既有商業產品組合成長、推進創新研發管線,以及進行未來的業務發展。我們的近期優先事項是推進兩家公司整合、確保關鍵成長動能維持在正軌上,並推動研發管線進展。
Integration planning has been underway, and we remain confident in capturing the $125 million of expected annual cost synergies that we previously discussed. With this merger on the verge of closing, we are entering an exciting new chapter that builds on a strong foundation. We expect to provide combined full-year 2027 guidance in February during the release of fourth quarter and full-year 2026 results. With that, I will now turn the call over to Tim.
整合規劃已在進行中,我們仍有信心實現先前討論的預期年度成本綜效 1.25 億美元。隨著本次合併即將完成交割,我們正邁入建立在堅實基礎上的嶄新篇章。我們預期將於 2 月發布第四季與 2026 全年業績時,提供合併後公司 2027 全年財測指引。接下來,我把電話交給 Tim。
Tim Dec - CFO
Tim Dec - CFO
Thank you, Jack. Good afternoon, everyone. As I review our third quarter 2026 results, please refer to today's press release and 10-Q that was filed earlier today. We achieved record total revenue of $226.8 million for the third quarter of 2026, an increase of 18% compared to the same quarter last year. Total revenue in the third quarter of 2026 was comprised of net product sales of $178.6 million, collaboration revenues associated with ZURZUVAE of $41.7 million, and royalties, licensing, and other revenues of $6.5 million. Please note, collaboration revenues represent approximately 50% of the sales of ZURZUVAE reported by Biogen. The increase in total revenues was primarily due to the increase in net sales of our growth products, Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. For the third quarter of 2026, combined R&D and SG&A expenses were $153.8 million, as compared to $209 million for the same quarter last year.
謝謝你,Jack。各位下午好。在我回顧我們 2026 年第三季的業績時,請參閱今天的新聞稿以及今日稍早提交的 10-Q。我們在 2026 年第三季達成創紀錄的總營收 2.268 億美元,較去年同期成長 18%。2026 年第三季總營收由以下項目構成:產品淨銷售額 1.786 億美元、與 ZURZUVAE 相關的合作收入 4,170 萬美元,以及權利金、授權與其他收入 650 萬美元。請注意,合作收入約代表 Biogen 所報告之 ZURZUVAE 銷售額的約 50%。總營收增加主要來自我們成長型產品 Qelbree、GOCOVRI、ZURZUVAE 與 ONAPGO 的產品淨銷售額增加。2026 年第三季研發(R&D)與銷售、一般及行政(SG&A)費用合計為 1.538 億美元,去年同期為 2.09 億美元。
Operating earnings on a GAAP basis for the third quarter of 2026 were $21.2 million, as compared to an operating loss of $60.2 million for the same quarter last year. The change was primarily due to the acquisition-related cost for the Sage acquisition in the third quarter of 2025, partially offset by higher revenues. GAAP net earnings were $20.9 million for the third quarter of 2026, or $0.35 per diluted share, compared to a GAAP net loss of $45.1 million, or a loss of $0.80 per diluted share in the same quarter of last year. On a non-GAAP basis, which excludes amortization of intangibles, share-based compensation, contingent consideration, and depreciation, adjusted operating earnings for the third quarter of 2026 was $55.2 million, compared to $41.9 million in the same quarter of the prior year. Total revenues for the first nine months of 2026 were $653.5 million.
2026 年第三季按 GAAP 基礎計算的營業利益為 2,120 萬美元,去年同期為營業虧損 6,020 萬美元。變動主要是由於 2025 年第三季收購 Sage 所產生的收購相關成本,部分被較高的營收所抵銷。2026 年第三季 GAAP 淨利為 2,090 萬美元,或每股稀釋盈餘 0.35 美元;相較之下,去年同期 GAAP 淨損為 4,510 萬美元,或每股稀釋虧損 0.80 美元。按非 GAAP 基礎(排除無形資產攤銷、股份基礎給付、或有對價及折舊),2026 年第三季調整後營業利益為 5,520 萬美元,去年同期為 4,190 萬美元。2026 年前九個月總營收為 6.535 億美元。
Excluding net product sales of Trokendi XR and Oxtellar XR, total revenues for the first nine months increased 37% compared to the same period last year. Total revenues were comprised of net product sales of $495 million, ZURZUVAE-related collaboration revenues of $104.7 million, and royalties, licensing, and other revenues of $53.8 million. Combined R&D and SG&A expenses for the nine months ending September 30th, 2026, were $481.5 million, as compared to $444.6 million for last year. The increase was primarily due to an increase in SG&A expenses associated with the collaboration agreement with Biogen. Operating loss on a GAAP basis for the first nine months was $45.1 million, as compared to an operating loss of $58.3 million for 2025.
若排除 Trokendi XR 與 Oxtellar XR 的產品淨銷售額,前九個月總營收較去年同期成長 37%。總營收由以下項目構成:產品淨銷售額 4.95 億美元、與 ZURZUVAE 相關的合作收入 1.047 億美元,以及權利金、授權與其他收入 5,380 萬美元。截至 2026 年 9 月 30 日止九個月,研發(R&D)與銷售、一般及行政(SG&A)費用合計為 4.815 億美元,去年為 4.446 億美元。增加主要是由於與 Biogen 的合作協議相關之 SG&A 費用增加。按 GAAP 基礎計算,前九個月營業虧損為 4,510 萬美元,相較 2025 年營業虧損 5,830 萬美元。
GAAP net loss was $39.8 million for the first nine months, or a loss of $0.69 per diluted share, compared to a GAAP net loss of $34.4 million, or $0.61 per diluted share in 2025. On a non-GAAP basis, which excludes amortization of intangibles, share-based compensation, contingent consideration, depreciation, and acquisition-related costs, adjusted operating earnings for the first nine months were $115.2 million, compared to $110.2 million for the same period last year. As of September 30th, 2026, the company had approximately $359 million in cash, cash equivalents, and marketable securities, compared to $309 million as of December 31st, 2025. Now turning to guidance. For full year 2026, the company, on a standalone basis, is raising its financial guidance for total revenue and non-GAAP operating earnings.
前九個月 GAAP 淨損為 3,980 萬美元,或每股稀釋虧損 0.69 美元;相較之下,2025 年 GAAP 淨損為 3,440 萬美元,或每股稀釋虧損 0.61 美元。按非 GAAP 基礎(排除無形資產攤銷、股份基礎給付、或有對價、折舊及收購相關成本),前九個月調整後營業利益為 1.152 億美元,去年同期為 1.102 億美元。截至 2026 年 9 月 30 日,公司持有約 3.59 億美元的現金、約當現金及有價證券;相較之下,截至 2025 年 12 月 31 日為 3.09 億美元。接下來談到財測指引。就 2026 全年而言,公司以獨立(standalone)基礎上調總營收與非 GAAP 營業利益的財務指引。
As such, we now expect full year 2026 total revenues to range from $875 million- $900 million, up from the previous guidance of $860 million- $890 million. And finally, we expect full year 2026 non-GAAP operating earnings to range from $160 million- $180 million, up from $150 million- $180 million. Assuming the merger with Indivior closes on November 2nd, this financial guidance will no longer apply. In terms of the merger, we are extremely excited about the closing of this transformative merger. Since we announced the deal in early August, a tremendous amount of work has been done on planning the integration of the two companies, and we are ready to begin executing that plan next week. As Jack mentioned, we are not providing 2027 guidance today, but we do expect to do that in February of 2027.
因此,我們目前預期 2026 全年總營收將介於 8.75 億至 9.00 億美元,高於先前指引的 8.60 億至 8.90 億美元。最後,我們預期 2026 全年非 GAAP 營業利益將介於 1.60 億至 1.80 億美元,高於先前的 1.50 億至 1.80 億美元。若與 Indivior 的合併於 11 月 2 日完成,則本財務指引將不再適用。就合併而言,我們對這項具轉型意義的合併完成感到非常振奮。自我們在 8 月初宣布交易以來,雙方已投入大量工作規劃兩家公司的整合,我們已準備好於下週開始執行該計畫。如 Jack 所提,我們今天不提供 2027 年指引,但我們預期將在 2027 年 2 月提供。
Finally, before we open the call to questions, please note that we would like to focus the Q&A on Supernus standalone results and outlook. As you can appreciate, we are limited in what we can discuss during this pending merger at this time, and we will do that at the appropriate time. With that, I now turn the call back over to the operator for Q&A.
最後,在我們開放提問之前,請注意我們希望將問答重點聚焦於 Supernus 的獨立(standalone)業績與展望。如各位所理解,在目前合併尚待完成期間,我們可討論的內容有限,我們會在適當時點再行說明。接下來我把電話交回給主持人進行問答。
Operator
Operator
(Operator Instructions) Kristen Kluska of Cantor Fitzgerald
(主持人指示) Cantor Fitzgerald 的 Kristen Kluska
Kristen Kluska - Analyst
Kristen Kluska - Analyst
Hi, everyone. Congrats on all the progress over the last quarter here. A couple of questions from me. First, on ZURZUVAE, I think the revenues here have been a lot higher than most of us expected when you first did this acquisition. I am curious if you and your partner feel like you are in a good position right now in terms of reps messaging out there, or if there is any plans to grow this. My second question on ONAPGO. I wanted to get an update on the timeline from the enrollment form submission to initial shipment. How has that changed over time, and do you expect it to continue or improve once you get the second manufacturer on board next year?
各位好。恭喜你們在上一季取得的所有進展。我有幾個問題。第一個關於 ZURZUVAE,我認為這裡的收入比我們多數人在你們最初進行這項收購時所預期的高出許多。我想了解你們與合作夥伴是否認為目前在外部業務代表(reps)訊息傳遞方面處於良好位置,或是否有任何擴大規模的計畫。第二個問題關於 ONAPGO。我想請你們更新一下從提交入組表單到首次出貨的時間表。這段時間隨著時間推移有何變化?以及在明年第二家製造商加入後,你們是否預期這個狀況會持續或有所改善?
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Yeah. Hi, Kristen. Regarding ZURZUVAE, the brand is doing extremely well, and we are very excited about how it is doing now, but also, more importantly, the future of the product. No matter what metric you look it has really been phenomenal as far as the growth of the product. Of course, this year we also started the DTC campaign. We have been very encouraged with what we have seen so far. Early metrics, but very good signals that there are a lot of great things that are coming out of that campaign. That is why we continue to see strong demand behind the product. All-time high metrics across the board, number of prescribers, patients, and so forth. We are really excited. So far, if you really look at the product since we launched it, we have only treated a little bit north of 40,000 patients since launch.
好的。嗨,Kristen。關於 ZURZUVAE,這個品牌表現非常出色,我們對目前的表現感到非常興奮,但更重要的是,對產品的未來也同樣充滿期待。不論你看哪一項指標,就產品成長而言都非常亮眼。當然,今年我們也啟動了 DTC(直接面向消費者)行銷活動。我們對目前看到的結果感到非常鼓舞。雖然仍是早期指標,但已出現非常好的訊號,顯示該活動將帶來許多正面成果。這也是為什麼我們持續看到產品背後的強勁需求。各項指標皆創歷史新高,包括開立處方的醫師數、患者數等等。我們真的非常興奮。截至目前,若你回頭看自上市以來的表現,我們自上市以來治療的患者人數僅略高於 40,000 人。
There is a lot of opportunity in front of us here. There are a lot of moms that need to really be aware of the disease, step forward, seek help. We are doing a lot of programs here to educate not just the consumer, the patient, but also on the healthcare provider side as well, to keep that momentum going behind the brand. As far as ONAPGO is concerned, given that in the second quarter, we pretty much relaunched the product and we went through the backlog that we had in the queue as far as the forms are concerned and processing them to actual shipments. All that backlog is now behind us. The third quarter was a nice clean quarter, so to speak, from that perspective. That gave us a little bit more time, actually, to even try to optimize the process.
我們眼前有很多機會。有很多媽媽確實需要提高對這種疾病的認知,主動站出來並尋求協助。我們在這裡推動了許多計畫,不僅教育消費者與病患,也同樣在醫療照護提供者端進行教育,以維持品牌背後的動能。就 ONAPGO 而言,鑑於第二季我們幾乎重新上市了該產品,並且就表單方面把佇列中累積的待處理案件清掉,將其處理並轉為實際出貨。目前所有積壓都已經處理完畢。從這個角度來看,第三季可以說是一個相當乾淨的季度。這也讓我們實際上有更多時間,甚至可以嘗試進一步優化流程。
We have done a lot of optimization and improvement in the process and the processing of the form to shipment. We are pretty much now back to normal timing as far as processing the form into shipments. We also have even improved a little bit on the conversion from form to shipments. A little bit every quarter there is more and more improvement as we go on because all the supply issues are behind us right now. A lot of the folks who are in the queue are pretty much fresh and new forms that have been submitted. We do not have any more patients who are waiting for a long time to be processed and to get their product and then get the training on it and so forth.
我們已在流程以及從表單處理到出貨的作業上做了大量優化與改善。就將表單處理成出貨的時程而言,我們現在基本上已回到正常水準。我們也在表單轉換為出貨的轉換率上略有提升。隨著時間推進,每一季都會有更多改善,因為目前所有供應問題都已經在我們身後了。佇列中的許多人基本上都是近期新提交的表單。我們不再有病患需要等待很長時間才能完成處理、拿到產品,然後接受相關訓練等等。
We are pretty happy that all that is behind us, and we continue to look forward here to focus on the demand and continue to build the demand. the demand, similarly, if you look, not different than ZURZUVAE, where we continue to see very good metrics, on aggregate across different metrics here, the prescriptions, number of patients on therapy, new writers, all have grown in the quarter versus the previous quarter.
我們很高興這些都已經過去了,接下來我們會持續把重點放在需求端,並持續建立需求。同樣地,就需求而言,如果你看一下,與 ZURZUVAE 類似,我們持續看到非常好的指標;綜合各項指標來看,處方量、接受治療的病患人數、新開立醫師數,在本季相較前一季都有成長。
Kristen Kluska - Analyst
Kristen Kluska - Analyst
Thanks and all the best and to the expected closing of the merger next week.
謝謝,祝一切順利,也預祝下週併購案如期完成交割。
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Thank you.
謝謝。
Operator
Operator
Stacy Ku of TD Cowen
TD Cowen 的 Stacy Ku
Stacy Ku - Equity Analyst
Stacy Ku - Equity Analyst
Hey there. Thanks so much for taking our questions. We have a couple. Something that we get asked by investors is around M&A. So with the merger set to close, Jack, is this a parallel track priority or something that might take some time to contemplate and execute on? So that's the first question that we do get a lot of inbounds on. Then a quick follow-up, as we think about spend and synergies. There's a guidance on synergies with Indivior for next year, but maybe also remind us where you are with Sage and spend, especially with the ZURZUVAE growth. Are there any additional synergies that can be realized over there? Is that all done? Then last, on Qelbree, just maybe talk about how net pricing is progressing and maybe expectations for the prescription trajectory for the rest of the year. Thanks so much.
嗨,你好。非常感謝你們回答我們的問題。我們有幾個問題。投資人常問我們的一個議題是併購(M&A)。因此,隨著這次合併即將完成交割,Jack,這會是並行推進的優先事項,還是可能需要一些時間來思考並執行?這是我們確實收到很多詢問的第一個問題。接著快速追問一下,關於支出與協同效益。你們對明年與 Indivior 的協同效益有提供指引,但也請提醒我們你們在 Sage 這邊的進度與支出情況,尤其是在 ZURZUVAE 成長之下。那邊是否還能實現任何額外的協同效益?還是已經都完成了?最後,關於 Qelbree,請談談淨定價的進展,以及對今年剩餘時間處方走勢的預期。非常感謝。
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Yeah. Regarding the M&A activity and whether it's a priority or not, we're always looking for potential opportunities to continue to grow our portfolio. This is something that you never and you're not able really to predict timing of these type of things, but we will continue to be active in looking and searching and identifying and building relationships within the industry, of course, with the appropriate targets and companies that we would like to do partnerships with them. As far as the top priorities, of course, six months after the merger, as I mentioned, we will be very focused on the integration of the two companies, Indivior and Supernus. So we will have plenty to do there. But during that time, of course, our BD group can continue to search for other opportunities for potential future transactions.
好的。關於併購活動以及它是否為優先事項,我們一直都在尋找潛在機會,以持續擴大我們的產品組合。這類事情的時點其實很難預測,但我們會持續積極地在產業內尋找、篩選機會並建立關係;當然,會鎖定我們希望合作的合適標的與公司,並與其進行合作夥伴關係。至於最優先事項,當然,如我所提,合併後的六個月內,我們會非常專注於 Indivior 與 Supernus 兩家公司的整合。因此那邊會有很多事情要做。但在此期間,當然,我們的商務開發(BD)團隊仍可持續尋找其他機會,以促成未來可能的交易。
Regarding the synergies, as far as the current merger that we're working on, as we mentioned in our prepared remarks, we feel pretty good about the target we put out there, the $125 million on an annual basis. So that we feel will be on track, and we're very confident with our ability to hit that number. And actually, more so because we just went through it pretty much related to your second question on Sage. We actually hit our target of $200 million on that transaction, maybe a little bit better we did. So we feel pretty good about our chances of hitting the target we have on the Indivior merger. And then regarding the last question, as far as Qelbree, overall big picture, Qelbree is doing really well. We're very pleased with Qelbree and the trends on the prescriptions.
關於協同效益,就我們目前正在推進的這次合併而言,如同我們在事先準備的發言中提到的,我們對外提出的目標——每年 1.25 億美元——我們感覺相當不錯。因此我們認為會按計畫推進,並且對達成該數字的能力非常有信心。而且更有信心的原因是,我們剛剛才經歷過這件事,這也回應你第二個關於 Sage 的問題:我們在那筆交易上達成了 2 億美元的目標,甚至可能還略優於目標。因此,我們對於在 Indivior 合併案上達成既定目標的機率感到相當樂觀。至於最後一個問題,關於 Qelbree,從整體大方向來看,Qelbree 表現非常好。我們對 Qelbree 以及處方趨勢都非常滿意。
Some of the things we haven't really mentioned, we don't talk about, but things like even if you look at new to brand prescriptions are up by 23% in the third quarter. We had a very strong third quarter, very strong growth in the number of prescribers. Overall, the brand is doing really well on the prescription side and specifically on the adult side, which is a very important segment that we continue to emphasize even during the back-to-school season, where typically we emphasize a little bit more on the pediatric because we want to build on the momentum of the back-to-school market dynamics. Even during that quarter, adults continued to outperform the pediatric growth. We're very pleased with both segments, the pediatric and the adult. And the product is so differentiated in the marketplace compared to the existing medications or even the recently approved products.
有些我們其實沒有特別提、也不太談的事情,例如即使你看「新進品牌(new-to-brand)」處方,第三季也成長了 23%。我們第三季表現非常強勁,開立處方的醫師人數成長也非常強。整體而言,品牌在處方端表現非常好,特別是在成人端;這是一個非常重要的區隔市場,我們持續強調,即使在返校季期間——通常我們會更著重兒科端,因為我們希望利用返校季的市場動態來延續動能。即便在那個季度,成人端的表現仍持續優於兒科端的成長。我們對兒科與成人兩個區隔都非常滿意。而且相較於現有藥物,甚至是近期核准的產品,這個產品在市場上具有非常明顯的差異化。
Qelbree has an incredibly unique position in the marketplace, has five years of experience. A lot of people have a lot of experience with the product now. We really feel pretty good about the position of the product, its delivery, and its future. Overall, we're still around 1% market share, and this market has been incredibly resilient and continues to grow at 10%+ in prescription, which is truly amazing in the CNS space. We feel really good about the future of Qelbree.
Qelbree 在市場上擁有極其獨特的定位,也累積了五年的使用經驗。現在很多人對這個產品已經有相當多的使用經驗。我們對產品的市場地位、交付(供應/配送)能力以及未來發展都相當有信心。整體而言,我們目前仍約為 1% 的市占率,而這個市場展現出極強的韌性,處方量持續以 10%+ 的速度成長,這在中樞神經(CNS)領域確實非常驚人。我們對 Qelbree 的未來感到非常樂觀。
Stacy Ku - Equity Analyst
Stacy Ku - Equity Analyst
Thanks so much. Appreciate it.
非常感謝。感激不盡。
Operator
Operator
Annabel Samimy of Stifel
Stifel 的 Annabel Samimy
Annabel Samimy - Analyst
Annabel Samimy - Analyst
Hi, it's Annabel. Thanks for taking my call. I know you're not really talking about the Supernus Indivior combination at this stage, but given that the combination is going to supply you with the balance sheet and the additional capital to potentially invest more in the space and in your own commercial portfolio, are there any specific initiatives, commercial initiatives that you're planning that you have been able to do before that could potentially facilitate continued growth of the products? For example, ZURZUVAE, have you moved into more of the OB-GYN space, and are you doing anything there to potentially enhance some of the growth of some of your current portfolio? Then, separately on ONAPGO, the 400 patient enrollment forms, is that a good run rate to start with?
嗨,我是 Annabel。謝謝接聽我的電話。我知道你們在這個階段不太談 Supernus 與 Indivior 的組合,但鑑於這次組合將為你們帶來資產負債表的支撐與額外資本,使你們可能在該領域以及你們自身的商業化產品組合上投入更多資源,你們是否規劃任何具體的策略或商業化措施——也就是以前可能做不到、但現在可以做——以促進產品持續成長?例如 ZURZUVAE,你們是否已更深入進入婦產科(OB-GYN)領域?在那方面是否有任何作為,可能用來提升你們現有產品組合的成長?另外,關於 ONAPGO,那 400 份病患入組表單,這樣的數量作為起步的運行速度(run rate)是否算不錯?
Because I know that it was sort of held back a little bit before, then you had a little bit of a bolus. So what is the right run rate for new patient enrollment forms for ONAPGO? Thanks.
因為我知道之前有點被壓抑了一段時間,然後你們又出現了一小波集中量(bolus)。那麼,ONAPGO 新病患入組表單的合理穩定提交速率(run rate)應該是多少?謝謝。
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Yeah, regarding the merger, that goes without saying. We're clearly going to be exploring all potential growth opportunities within the, as I mentioned in my remarks, within our existing portfolio, which would be, of course, SUBLOCADE, Qelbree, ONAPGO, ZURZUVAE and so forth. So that will be one of the key areas where we would look at what else can we do? Are there any other programs we would like to consider, and so forth. So that's something definitely we'll be looking at to maximize these brands, all of them, and maximize their potential and growth in the future. Then as far as ONAPGO and the run rate, it's been around the 400. It ticked up a little bit, but it's been around the 400, 425. It bounces around a little bit. So at this point, it looks like it's a good run rate as an assumption.
是的,關於併購,這點不言而喻。很明顯,我們將會探索所有潛在的成長機會——如我在發言中提到的——在我們現有產品組合之內,當然包括 SUBLOCADE、Qelbree、ONAPGO、ZURZUVAE 等等。因此,這將是我們會去思考「還能做些什麼」的關鍵領域之一。是否有其他我們想要考慮的專案等等。所以我們肯定會著手評估,以在未來最大化這些品牌——全部品牌——並最大化其潛力與成長。至於 ONAPGO 的 run rate,大約在 400 左右。有小幅上升,但大致在 400、425 之間。會有些波動。所以就目前來看,把它當作假設的合理 run rate 似乎沒問題。
Of course, we're working pretty hard to even increase it more and continue to grow it hopefully as time goes on.
當然,我們也在非常努力地希望把它再提高一些,並隨著時間推進持續成長。
Annabel Samimy - Analyst
Annabel Samimy - Analyst
Great. Thank you.
很好。謝謝。
Operator
Operator
Chi Fong of BofA
美國銀行(BofA)的 Chi Fong
Chi Fong - Analyst
Chi Fong - Analyst
Hey, guys. Thanks for taking my questions. First one I have is, I want to ask about just the operating margin. Looking at the 3Q results and the guidance of the midpoint imply roughly around mid-20% margin, better than the mid-teens in the first two quarters. As we think about Supernus as the current standalone entity, where is the opportunity for margin expansion next year relative to current level? Is it fair to assume a higher operating margin than the 20% implied in a 2026 guidance for Supernus as a standalone entity?
嗨,各位。謝謝回答我的問題。第一個問題,我想問的是營業利潤率(operating margin)。從第三季(3Q)結果以及指引中位數來看,隱含大約是 20% 中段的利潤率,優於前兩季的 10% 中段。如果把 Supernus 視為目前獨立運作的公司,明年相較於目前水準,利潤率擴張的機會在哪裡?是否可以合理假設,若 Supernus 仍為獨立公司,其營業利潤率會高於 2026 年指引所隱含的 20%?
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Yeah, regarding theâthis is a little bit of a difficult question because we're going to assume something that's not going to happen, and the dynamics will change, of course, once you have the merged company. But assume standalone and there is no merger or whatever, clearly, as time goes on, our plan has been to continue to improve our operating margin. That goes without saying because it's a natural phase that you go through as you launch products, you invest behind them, you expand, you spend money on launching some of these products. Naturally, as time goes on, you'll be able to improve the operating margin because your investment level might not be exactly the same forever. You'll do that commensurate with the life cycle of every product. Naturally, the short answer is yes, we would have been able to improve our operating margin.
是的,關於這個——這是一個有點難回答的問題,因為我們要假設一個不會發生的情境,而一旦合併後,動態當然會改變。但如果假設獨立經營、沒有合併或其他情況,隨著時間推進,我們的計畫一直是持續改善營業利潤率。這不言而喻,因為這是產品上市後自然會經歷的階段:你推出產品、在背後投入資源、擴張、為某些產品上市投入費用。自然地,隨著時間推進,你將能改善營業利潤率,因為你的投資水準不可能永遠都一樣。你會依各產品的生命週期來做相應調整。所以簡短答案是:是的,我們本來就能夠改善營業利潤率。
Of course, these comments only apply to Supernus as standalone. With the new company, we will have a lot of different dynamics at that point.
當然,這些評論只適用於 Supernus 作為獨立公司。在新公司之下,屆時會有許多不同的動態。
Chi Fong - Analyst
Chi Fong - Analyst
Got it. My second question, I want to ask about SPN-817 which is currently in phase II development for epilepsy. I am curious, can you talk about timing of the data and expectation for the readout?
了解。第二個問題,我想問目前用於癲癇、正處於第二期(phase II)開發的 SPN-817。我很好奇,你能談談數據的時間點以及對讀出(readout)的預期嗎?
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Yeah. Right now, given the rate of recruitment, it looks like most likely, and we will confirm that with a little bit more concrete data. We would like to see another quarter of recruitment before we put out a specific target. But it looks like it is going to be in 2028. I do not have more specifics as in first quarter, second quarter, third quarter. We will come back with more information as we get better feel for the recruitment. These epilepsy trials tend to be slow in general. So we are basically going at very similar rates as everybody else in the industry in doing these trials. So 2028 will be a good guess, but when in 2028, we will try to nail it down and get it a little tighter as time goes on.
好的。目前依照招募速度來看,最有可能——我們也會用更具體的數據來確認——我們希望再觀察一個季度的招募情況,再對外給出明確的目標時間。但看起來會是在 2028 年。我沒有更細的資訊,例如是第一季、第二季或第三季。等我們對招募進度有更好的掌握後,會再帶回更多資訊。這類癲癇試驗一般來說都偏慢。所以我們基本上是以與產業其他公司非常相近的速度在進行這些試驗。因此,2028 年會是個合理的推測;至於 2028 年的哪個時間點,我們會隨著時間推進,努力把它釘得更精準一些。
Chi Fong - Analyst
Chi Fong - Analyst
If I may squeeze one in. This is a follow-up to Annabel's questions earlier. So curious, obviously more than 400 new forms were submitted for ONAPGO this quarter, similar to the run rate the first couple of quarters. Jack, were you surprised that the number of new forms submitted have not picked up meaningfully since the resolution of the supply shortage? Looking ahead, what are the upside levers that new forms and new scripts could pick up meaningfully from current run rate?
如果我可以再塞一個問題。這是對先前 Annabel 問題的追問。所以我好奇,顯然本季 ONAPGO 提交的新表單超過 400 份,與前幾季的 run rate 類似。Jack,在供應短缺問題解決之後,新表單提交數量沒有明顯回升,你有感到意外嗎?展望未來,有哪些上行驅動因素(upside levers)能讓新表單與新處方(new scripts)相較目前 run rate 出現更顯著的提升?
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Yeah. The answer to the first question, it wasn't surprising because we knew we were relaunching the product, basically. Not that we're starting from scratch, but when you pause for three, four months, the heavy activity from a launch perspective, everybody slows down because of the supply issues, and now you start again. Naturally, you are more in a relaunch mode. We're really actually pretty pleased with the levels of forms that we have. We always would love to have more, don't get me wrong. Clearly, as I mentioned earlier, now that we have all these issues behind us, the supply, and as I mentioned earlier, the process also has gotten much smoother because the backlog is all cleared up. The conversion could potentially get better. All these will help us continue to feed the demand.
是的。第一個問題的答案是:不意外,因為我們知道基本上是在重新啟動(relaunch)這個產品。不是說從零開始,但當你暫停三、四個月時,從上市推廣的角度來看,因供應問題大家的高強度活動都會放慢,現在則是重新開始。自然地,你會更像是在「再上市」的模式。其實我們對目前的表單量水準相當滿意。我們當然永遠希望更多,別誤會。很明顯,如我先前提到的,現在這些問題都已經在我們身後了——供應問題;而且如我先前所說,流程也順暢許多,因為積壓都已清除。轉換率(conversion)可能會變得更好。這些都將幫助我們持續滿足需求。
Physicians will get positive and more positive feedback on the experience that their patients are having with the product. All this will help us, hopefully, make this a growing number as time goes on, beyond the 400 and go above that. Clearly stay tuned to any updates as time goes on, but we feel pretty good about the basics for the demand of this product. Yeah.
醫師會收到正面、而且越來越正面的回饋,關於他們的病患使用這個產品的體驗。希望這些都能幫助我們,隨著時間推進,讓這個數字持續成長,超過 400 並再往上。很明顯,後續如有更新請持續關注,但我們對這個產品需求面的基本面感覺相當不錯。是的。
Chi Fong - Analyst
Chi Fong - Analyst
Okay, great. Thanks so much.
好的,很棒。非常感謝。
Operator
Operator
I am not showing any more questions at this time. I will now turn it back over to Jack Khattar, President and CEO, for closing remarks.
目前我這邊沒有看到更多問題。接下來我將把電話交回給總裁兼執行長 Jack Khattar 作結語。
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Jack Khattar - President, Chief Executive Officer, Secretary, Director
Thank you for joining us on this call today. We have positive momentum across our business, as evident with our strong third quarter and year-to-date performance in 2026. We continue to generate strong cash flows behind the strength of our growth products and through the efficiency of our operations. We are very excited about our future as a combined company with Indivior and the value it will create. Thanks again for joining us this afternoon. We look forward to providing you with further updates on our progress.
感謝各位今天參與本次電話會議。我們的業務整體呈現正向動能,從 2026 年第三季以及年初至今的強勁表現即可看出。憑藉成長型產品的強勢表現以及營運效率,我們持續創造強勁的現金流。我們對於與 Indivior 合併後作為一家整合公司之未來,以及其將創造的價值,感到非常振奮。再次感謝各位今天下午加入我們。我們期待在未來向各位提供更多進展更新。
Operator
Operator
Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.
感謝各位參與今天的會議。本次議程到此結束。您現在可以掛線。